Advanced

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

Astermark, Jan LU ; Morado, M; Rocino, A; van den Berg, H M; von Depka, M; Gringeri, A; Mantovani, L; Garrido, R P; Schiavoni, M and Villar, A, et al. (2006) In Haemophilia 12(4). p.363-371
Abstract
The management of patients with inhibitors is an important challenge in haemophilia care. The lack of randomized controlled trials means that clinical decisions are generally based on subjective opinions, and purchasers' attention is likely to focus on the costs of treatment. In order to assess the current management of inhibitor patients and use of immune tolerance induction therapy (ITI) in Europe, we performed a survey within a European network of 21 comprehensive care centres from 14 countries (the European Haemophilia Therapy Standardisation Board). The survey identified a total of 381 patients with inhibitors attending the centres, 211 (55.4%) of whom had never been exposed to ITI. Between 1998 and 2003, the centres performed 233... (More)
The management of patients with inhibitors is an important challenge in haemophilia care. The lack of randomized controlled trials means that clinical decisions are generally based on subjective opinions, and purchasers' attention is likely to focus on the costs of treatment. In order to assess the current management of inhibitor patients and use of immune tolerance induction therapy (ITI) in Europe, we performed a survey within a European network of 21 comprehensive care centres from 14 countries (the European Haemophilia Therapy Standardisation Board). The survey identified a total of 381 patients with inhibitors attending the centres, 211 (55.4%) of whom had never been exposed to ITI. Between 1998 and 2003, the centres performed 233 procedures and 114 (48.9%) were successful. The survey demonstrated that dosing, which is the time to start and stop the ITI, the type of concentrate to use and the definition of success varied among the centres. Well-designed trials are warranted to guide decision-making, but in the absence of these studies we have developed consensus guidance for the management of inhibitor patients based on current clinical practice, as identified by the survey, and review of the literature. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
inhibitors, immune tolerance therapy, survey, haemophilia
in
Haemophilia
volume
12
issue
4
pages
363 - 371
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000238486400005
  • scopus:34248220822
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2006.01296.x
language
English
LU publication?
yes
id
f1145985-cace-4ae9-87a4-793138e89c59 (old id 159058)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16834735&dopt=Abstract
date added to LUP
2007-07-11 13:31:43
date last changed
2019-07-30 02:12:11
@article{f1145985-cace-4ae9-87a4-793138e89c59,
  abstract     = {The management of patients with inhibitors is an important challenge in haemophilia care. The lack of randomized controlled trials means that clinical decisions are generally based on subjective opinions, and purchasers' attention is likely to focus on the costs of treatment. In order to assess the current management of inhibitor patients and use of immune tolerance induction therapy (ITI) in Europe, we performed a survey within a European network of 21 comprehensive care centres from 14 countries (the European Haemophilia Therapy Standardisation Board). The survey identified a total of 381 patients with inhibitors attending the centres, 211 (55.4%) of whom had never been exposed to ITI. Between 1998 and 2003, the centres performed 233 procedures and 114 (48.9%) were successful. The survey demonstrated that dosing, which is the time to start and stop the ITI, the type of concentrate to use and the definition of success varied among the centres. Well-designed trials are warranted to guide decision-making, but in the absence of these studies we have developed consensus guidance for the management of inhibitor patients based on current clinical practice, as identified by the survey, and review of the literature.},
  author       = {Astermark, Jan and Morado, M and Rocino, A and van den Berg, H M and von Depka, M and Gringeri, A and Mantovani, L and Garrido, R P and Schiavoni, M and Villar, A and Windyga, J},
  issn         = {1351-8216},
  keyword      = {inhibitors,immune tolerance therapy,survey,haemophilia},
  language     = {eng},
  number       = {4},
  pages        = {363--371},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2006.01296.x},
  volume       = {12},
  year         = {2006},
}